Cargando…
PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
SIMPLE SUMMARY: Despite the large use of inhibitors of Poly-ADP ribose polymerase (PARP-I), the feasibility and safety of their combination with radiotherapy (RT) are unclear. The combination may be particularly interesting in the oligometastatic setting in which patients may benefit from local RT d...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582502/ https://www.ncbi.nlm.nih.gov/pubmed/34771545 http://dx.doi.org/10.3390/cancers13215380 |
_version_ | 1784597001554362368 |
---|---|
author | Barcellini, Amelia Loap, Pierre Murata, Kazutoshi Villa, Riccardo Kirova, Youlia Okonogi, Noriyuki Orlandi, Ester |
author_facet | Barcellini, Amelia Loap, Pierre Murata, Kazutoshi Villa, Riccardo Kirova, Youlia Okonogi, Noriyuki Orlandi, Ester |
author_sort | Barcellini, Amelia |
collection | PubMed |
description | SIMPLE SUMMARY: Despite the large use of inhibitors of Poly-ADP ribose polymerase (PARP-I), the feasibility and safety of their combination with radiotherapy (RT) are unclear. The combination may be particularly interesting in the oligometastatic setting in which patients may benefit from local RT during the treatment with PARP-I. The aim of the current review was to evaluate the outcome and the toxicity in patients with newly diagnosed or recurrent tumors treated with a combination of PARP-I and RT. A total of 12 clinical studies met the inclusion criteria and, despite the heterogeneity of the evaluated patient populations and tumor types, this review suggests that a combination approach is feasible even though the efficacy profile remains unclear. ABSTRACT: Background: Despite the large use of inhibitors of Poly-ADP ribose polymerase (PARP-I), the feasibility and safety of their combination with radiotherapy (RT) is unclear. Aim: We conducted a literature analysis with the aim to evaluate the efficacy and safety profile of a combination with RT and PARP-I. Method: The key issues for the current review were expressed in two questions according to the Population, Intervention, Control, Outcome (PICO) criteria: 1. What is the outcome and 2. What is the toxicity in patients treated with a combination of PARP-I and RT for a newly diagnosed or recurrent tumors? Results: A total of 12 clinical studies met the inclusion criteria including seven single-arm dose-escalation phase I studies, two phase II (two- and three-arms controlled trials) trials, one parallel-arm phase I study, and two phase I/II studies published between 2015 and 2021. RT was performed with photon beams and several schedules according to the clinical situation. The acute toxicity ≥ grade 3 ranged between 25% and >96%, which was divided into hematological or non-hematological adverse events. Conclusions: despite the heterogeneity of the evaluated patient populations and tumor types, and the limited number of the studies, this review suggests that a combination approach is feasible even though the efficacy profile remains unclear. |
format | Online Article Text |
id | pubmed-8582502 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85825022021-11-12 PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do? Barcellini, Amelia Loap, Pierre Murata, Kazutoshi Villa, Riccardo Kirova, Youlia Okonogi, Noriyuki Orlandi, Ester Cancers (Basel) Review SIMPLE SUMMARY: Despite the large use of inhibitors of Poly-ADP ribose polymerase (PARP-I), the feasibility and safety of their combination with radiotherapy (RT) are unclear. The combination may be particularly interesting in the oligometastatic setting in which patients may benefit from local RT during the treatment with PARP-I. The aim of the current review was to evaluate the outcome and the toxicity in patients with newly diagnosed or recurrent tumors treated with a combination of PARP-I and RT. A total of 12 clinical studies met the inclusion criteria and, despite the heterogeneity of the evaluated patient populations and tumor types, this review suggests that a combination approach is feasible even though the efficacy profile remains unclear. ABSTRACT: Background: Despite the large use of inhibitors of Poly-ADP ribose polymerase (PARP-I), the feasibility and safety of their combination with radiotherapy (RT) is unclear. Aim: We conducted a literature analysis with the aim to evaluate the efficacy and safety profile of a combination with RT and PARP-I. Method: The key issues for the current review were expressed in two questions according to the Population, Intervention, Control, Outcome (PICO) criteria: 1. What is the outcome and 2. What is the toxicity in patients treated with a combination of PARP-I and RT for a newly diagnosed or recurrent tumors? Results: A total of 12 clinical studies met the inclusion criteria including seven single-arm dose-escalation phase I studies, two phase II (two- and three-arms controlled trials) trials, one parallel-arm phase I study, and two phase I/II studies published between 2015 and 2021. RT was performed with photon beams and several schedules according to the clinical situation. The acute toxicity ≥ grade 3 ranged between 25% and >96%, which was divided into hematological or non-hematological adverse events. Conclusions: despite the heterogeneity of the evaluated patient populations and tumor types, and the limited number of the studies, this review suggests that a combination approach is feasible even though the efficacy profile remains unclear. MDPI 2021-10-27 /pmc/articles/PMC8582502/ /pubmed/34771545 http://dx.doi.org/10.3390/cancers13215380 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Barcellini, Amelia Loap, Pierre Murata, Kazutoshi Villa, Riccardo Kirova, Youlia Okonogi, Noriyuki Orlandi, Ester PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do? |
title | PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do? |
title_full | PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do? |
title_fullStr | PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do? |
title_full_unstemmed | PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do? |
title_short | PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do? |
title_sort | parp inhibitors in combination with radiotherapy: to do or not to do? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582502/ https://www.ncbi.nlm.nih.gov/pubmed/34771545 http://dx.doi.org/10.3390/cancers13215380 |
work_keys_str_mv | AT barcelliniamelia parpinhibitorsincombinationwithradiotherapytodoornottodo AT loappierre parpinhibitorsincombinationwithradiotherapytodoornottodo AT muratakazutoshi parpinhibitorsincombinationwithradiotherapytodoornottodo AT villariccardo parpinhibitorsincombinationwithradiotherapytodoornottodo AT kirovayoulia parpinhibitorsincombinationwithradiotherapytodoornottodo AT okonoginoriyuki parpinhibitorsincombinationwithradiotherapytodoornottodo AT orlandiester parpinhibitorsincombinationwithradiotherapytodoornottodo |